AstraZeneca Wins Scrip Award for “Best Partnership Alliance”
Friday, 4 November 2011
AstraZeneca has won the prestigious Scrip Award for “Best Partnership Alliance” for the three-way colorectal cancer collaboration between AstraZeneca, Agendia and the Netherlands Cancer Institute in the 7th annual competition, which acknowledges and celebrates the highest achievers in the pharmaceutical industry.
This is the second year running that AstraZeneca has won the ‘Best Partnership Alliance’ category of the Scrip Intelligence Awards. Scrip, the leading source for global pharmaceutical industry news, convenes an independent judging panel comprised of senior pharmaceutical industry experts, to award innovation for a range of industry activities, including novel deals, new drug launches, and breakthrough clinical trials. The Best Partnership Alliance award recognises the importance of partnerships involving pharmaceutical and/or biotech companies in developing novel therapeutics. View the award press release
The objectives of the award-winning AstraZeneca, Agendia and the Netherlands Cancer Institute collaboration are to segment colorectal cancer at the molecular level and identify and validate new targets with personalized healthcare markers in defined patient populations with a view to providing the basis to discover and develop novel medicines suited to individual disease types in colorectal cancer.
Iris Simon, Senior Director of Research and Development at Agendia commented on the award, "Our alliance between NKI, Agendia and AstraZeneca has a unique structure by bringing together high level academic research with companies known for the successful development of molecular diagnostics and targeted therapies, respectively. We are delighted that the Scrip award committee has recognised the successful efforts and future potential of this alliance."
Commenting on the Partnership Alliance Award Shaun Grady, VP Strategic Partnering and Business Development, said:
The Scrip award is industry endorsement of AstraZeneca’s commitment to externalisation and the value we place on mutually-beneficial collaborations to meet unmet medical need.